Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded ...

Developed by international researchers led by British experts, RI-AG03, tackles two 'hotspots' on the protein that leads to ...

An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...

A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...

RESEARCHERS have developed a drug that successfully blocks two major Alzheimer’s disease “hotspots” at once, in a “promising” breakthrough against the brain robbing ...

The 829 registered participants from 156 teams in Sunday's Walk to End Alzheimer's Northern Virginia, held at Reston Town ...

According to the latest Morning Thoughts post, Eli Lilly’s Alzheimer’s drug, donanemab (brand name Kisunla), was approved in Japan for treating early symptomatic Alzheimer’s disease ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...

We spoke to Andrew Doig, professor of biochemistry at the University of Manchester, to find out more about the evolving ...

Annovis Bio saw promising results for Buntanetap in treating Alzheimer's and Parkinson's, but short cash runway prompts a ...